Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
- 11 July 2019
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 82 (6), 1490-1500
- https://doi.org/10.1016/j.jaad.2019.07.005
Abstract
No abstract availableKeywords
Funding Information
- Biofrontera
- SunPharma
This publication has 57 references indexed in Scilit:
- Erratum to: Thanks to all those who reviewed for systematic reviews in 2014Systematic Reviews, 2015
- Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantationJournal for ImmunoTherapy of Cancer, 2015
- Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic MelanomaJournal of Immunotherapy, 2015
- Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient dataBMJ, 2014
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic MelanomaJournal of Clinical Oncology, 2014
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplantsImmunobiology, 2011
- CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanismsNature Immunology, 2009
- Reduction of immunosuppression for transplant-associated skin cancer: expert consensus surveyBritish Journal of Dermatology, 2006
- THE RISK OF SKIN CANCER IN RENAL TRANSPLANT RECIPIENTS IN QUEENSLAND, AUSTRALIATransplantation, 1996